24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading multi-site clinical trial company, is proud to announce…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney,…
NEWPORT BEACH, Calif., Sept. 24, 2025 /PRNewswire/ -- HYVE Labs™ and MindHYVE.ai™ proudly announce the global launch of ChironAI™, an…
OIC India Enhances On-Site Capabilities with Structured Clinical and Digital Dentistry Training SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ --…
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative…
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company…